EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. MATERIAL TRANSFER AND RESEARCH AGREEMENTMaterial Transfer and Research Agreement • May 30th, 2023 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Agreement is made as of May 8, 2023 (“Effective Date”) by and between AIM IMMUNOTECH INC. (“AIM”), a corporation incorporated under the laws of Delaware, having an Offices at 2117 SW Hwy 484 Ocala Fl 34473 as the supplier of the experimental drug Ampligen® and Japanese National Institute of Infectious Disease (“NIID”) with its address at Toyama 1-23-1, Shinjuku-ku Tokyo 162-8640, Japan, (NIID”). AIM and NIID shall be referred to individually as a “Party” and together as the “Parties.”
